<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37607205</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Spinal cord and brain concentrations of riluzole after oral and intrathecal administration: A potential new treatment route for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e0277718</StartPage><MedlinePgn>e0277718</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0277718</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0277718</ELocationID><Abstract><AbstractText>Riluzole is the only treatment known to improve survival in patients with Amyotrophic Lateral Sclerosis (ALS). However, oral riluzole efficacy is modest at best, further it is known to have large inter-individual variability of serum concentration and clearance, is formulated as an oral drug in a patient population plagued with dysphagia, and has known systemic side-effects like asthenia (limiting patient compliance) and elevated liver enzymes. In this context, we postulated that continuous intrathecal (IT) infusion of low doses of riluzole could provide consistent elevations of the drug spinal cord (SC) concentrations at or above those achieved with oral dosing, without increasing the risk for adverse events associated with systemic drug exposure or off-target side effects in the brain. We developed a formulation of riluzole for IT delivery and conducted our studies in purpose-bred hound dogs. Our non-GLP studies revealed that IT infusion alone was able to increase SC concentrations above those provided by oral administration, without increasing plasma concentrations. We then conducted two GLP studies that combined IT infusion with oral administration at human equivalent dose, to evaluate SC and brain concentrations of riluzole along with assessments of safety and tolerability. In the 6-week study, the highest IT dose (0.2 mg/hr) was well tolerated by the animals and increased SC concentrations above those achieved with oral riluzole alone, without increasing brain concentrations. In the 6-month study, the highest dose tested (0.4 mg/hr) was not tolerated and yielded SC significantly above those achieved in all previous studies. Our data show the feasibility and safety profile of continuous IT riluzole delivery to the spinal cord, without concurrent elevated liver enzymes, and minimal brain concentrations creating another potential therapeutic route of delivery to be used in isolation or in combination with other therapeutics."</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Keifer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keifer</LastName><ForeName>Orion P</ForeName><Initials>OP</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0003-1040-0983</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Juanmarco</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Tox Path Specialists, LLC (a StageBio Company), Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Sarah D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0003-4687-1971</Identifier><AffiliationInfo><Affiliation>Tox Path Specialists, LLC (a StageBio Company), Frederick, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartus</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>RTBioconsultants, San Diego, CA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tansey</LastName><ForeName>Malu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Emory University School of Medicine, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deaver</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Deaver Non-Clinical Drug Development Consulting, LLC, Franklin, MA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betourne</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Above and Beyond NB LLC, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulis</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0002-7271-3953</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Nicholas M Boulis is a consultant for Abbott, UCB, Novo Nordisk, Treefrog, UniQure, and Coave. He serves on the scientific advisory board for Above and Beyond NB LLC. Raymond T. Bartus was a consultant and advisor for Above and Beyond NB LLC. Mal&#xfa; G Tansey is a consultant for INmune Bio, Longevity, and Prevail Therapeutics. She serves on the scientific advisory board for the Garfield Weston Foundation, the Michael J Fox Foundation, the Quebec Parkinson&#x2019;s Network, and the Alzheimer&#x2019;s Association. She receives research support from the NIH, the MJ Fox Foundation, and the Parkinson&#x2019;s Foundation. Above and Beyond NB LLC&#x2019;s riluzole formulation is protected by a use patent issued June 18th 2019 (N&#xb0;10,322,114).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>13</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37607205</ArticleId><ArticleId IdType="pmc">PMC10443869</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0277718</ArticleId><ArticleId IdType="pii">PONE-D-22-29890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1185&#x2013;207. doi: 10.1212/01.CON.0000455886.14298.a4. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.CON.0000455886.14298.a4</ArticleId><ArticleId IdType="pubmed">25299277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al.. Prevalence of Amyotrophic Lateral Sclerosis&#x2014;United States, 2012&#x2013;2013. MMWR Surveill Summ. 2016;65(8):1&#x2013;12. doi: 10.15585/mmwr.ss6508a1. .</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.ss6508a1</ArticleId><ArticleId IdType="pubmed">27490513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder DW. Clinical limits of amyotrophic lateral sclerosis. Adv Neurol. 1982;36:15&#x2013;22. .</Citation><ArticleIdList><ArticleId IdType="pubmed">7180681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688&#x2013;700. doi: 10.1056/NEJM200105313442207. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Tard C, Defebvre L, Moreau C, Devos D, Danel-Brunaud V. Clinical features of amyotrophic lateral sclerosis and their prognostic value. Rev Neurol (Paris). 2017;173(5):263&#x2013;72. Epub 2017/05/10. doi: 10.1016/j.neurol.2017.03.029. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.03.029</ArticleId><ArticleId IdType="pubmed">28477850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol. 1993;240(6):339&#x2013;46. Epub 1993/06/01. doi: 10.1007/BF00839964. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00839964</ArticleId><ArticleId IdType="pubmed">8336173</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chio A, Couratier P, Mitchell JD, et al.. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79(1):6&#x2013;11. Epub 2007/12/15. doi: 10.1136/jnnp.2006.104828. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.104828</ArticleId><ArticleId IdType="pubmed">18079297</ArticleId></ArticleIdList></Reference><Reference><Citation>Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997&#x2013;2011. Neurol Clin Pract. 2013;3(4):313&#x2013;20. Epub 2013/11/07. doi: 10.1212/CPJ.0b013e3182a1b8ab. ; PubMed Central PMCID: PMC3787117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0b013e3182a1b8ab</ArticleId><ArticleId IdType="pmc">PMC3787117</ArticleId><ArticleId IdType="pubmed">24195020</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King&#x2019;s database 1990&#x2013;2002. J Neurol Neurosurg Psychiatry. 2003;74(7):995&#x2013;7. Epub 2003/06/18. doi: 10.1136/jnnp.74.7.995. ; PubMed Central PMCID: PMC1738535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.7.995</ArticleId><ArticleId IdType="pmc">PMC1738535</ArticleId><ArticleId IdType="pubmed">12810805</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, et al.. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci. 1993;118(1):48&#x2013;55. Epub 1993/08/01. doi: 10.1016/0022-510x(93)90245-t. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(93)90245-t</ArticleId><ArticleId IdType="pubmed">8229050</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al.. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;7. Epub 2014/10/07. doi: 10.3109/21678421.2014.959024. ; PubMed Central PMCID: PMC4266079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;12. Epub 2017/05/20. doi: 10.1016/S1474-4422(17)30115-1. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;91. doi: 10.1056/NEJM199403033300901. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2013;31. doi: 10.1016/s0140-6736(96)91680-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch. 1991;419(6):603&#x2013;9. Epub 1991/12/01. doi: 10.1007/BF00370302. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00370302</ArticleId><ArticleId IdType="pubmed">1664937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol. 1994;45(5):1055&#x2013;60. Epub 1994/05/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">8190096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagoshi N, Nakashima H, Fehlings MG. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules. 2015;20(5):7775&#x2013;89. doi: 10.3390/molecules20057775. .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules20057775</ArticleId><ArticleId IdType="pmc">PMC6272473</ArticleId><ArticleId IdType="pubmed">25939067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al.. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47(6 Suppl 4):S242&#x2013;50. doi: 10.1212/wnl.47.6_suppl_4.242s .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.47.6_suppl_4.242s</ArticleId><ArticleId IdType="pubmed">8959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Riluzole [package insert]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2008.</Citation></Reference><Reference><Citation>van Kan HJ, van den Berg LH, Groeneveld GJ, van der Straaten RJ, van Vught PW, Lie AHL, et al.. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype. Biopharm Drug Dispos. 2008;29(3):139&#x2013;44. Epub 2007/12/22. doi: 10.1002/bdd.594. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdd.594</ArticleId><ArticleId IdType="pubmed">18098330</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, Markandaiah SS, Jacob D, Meng NJ, Li K, Gennaro V, et al.. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol. 2014;1(12):996&#x2013;1005. doi: 10.1002/acn3.141. ; PubMed Central PMCID: PMC4284125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.141</ArticleId><ArticleId IdType="pmc">PMC4284125</ArticleId><ArticleId IdType="pubmed">25574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane A, Fernandez C, Vautier S, Bensimon G, Meininger V, Farinotti R. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem. 2007;103(1):164&#x2013;73. doi: 10.1111/j.1471-4159.2007.04772.x. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04772.x</ArticleId><ArticleId IdType="pubmed">17635670</ArticleId></ArticleIdList></Reference><Reference><Citation>Milane A, Tortolano L, Fernandez C, Bensimon G, Meininger V, Farinotti R. Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J Pharm Pharm Sci. 2009;12(2):209&#x2013;17. doi: 10.18433/j36c78 .</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/j36c78</ArticleId><ArticleId IdType="pubmed">19732498</ArticleId></ArticleIdList></Reference><Reference><Citation>Onesti E, Schettino I, Gori MC, Frasca V, Ceccanti M, Cambieri C, et al.. Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management. Front Neurol. 2017;8:94. Epub 2017/04/06. doi: 10.3389/fneur.2017.00094. ; PubMed Central PMCID: PMC5359548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00094</ArticleId><ArticleId IdType="pmc">PMC5359548</ArticleId><ArticleId IdType="pubmed">28377742</ArticleId></ArticleIdList></Reference><Reference><Citation>Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430(1&#x2013;2):197&#x2013;206. Epub 2012/04/25. doi: 10.1016/j.ijpharm.2012.04.022. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2012.04.022</ArticleId><ArticleId IdType="pubmed">22525080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf. 2004;3(6):525&#x2013;34. doi: 10.1517/14740338.3.6.525 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.3.6.525</ArticleId><ArticleId IdType="pubmed">15500412</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D. Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. Psychosomatics. 2013;54(5):488&#x2013;92. doi: 10.1016/j.psym.2013.02.002. ; PubMed Central PMCID: PMC3681895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psym.2013.02.002</ArticleId><ArticleId IdType="pmc">PMC3681895</ArticleId><ArticleId IdType="pubmed">23473447</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington Study G. Dosage effects of riluzole in Huntington&#x2019;s disease: a multicenter placebo-controlled study. Neurology. 2003;61(11):1551&#x2013;6. doi: 10.1212/01.wnl.0000096019.71649.2b .</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000096019.71649.2b</ArticleId><ArticleId IdType="pubmed">14663041</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. J Clin Psychopharmacol. 2008;28(3):363&#x2013;7. doi: 10.1097/JCP.0b013e3181727548. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0b013e3181727548</ArticleId><ArticleId IdType="pubmed">18480706</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al.. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161(1):171&#x2013;4. doi: 10.1176/appi.ajp.161.1.171. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.161.1.171</ArticleId><ArticleId IdType="pubmed">14702270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al.. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57(4):430&#x2013;2. doi: 10.1016/j.biopsych.2004.11.023. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2004.11.023</ArticleId><ArticleId IdType="pubmed">15705360</ArticleId></ArticleIdList></Reference><Reference><Citation>McClelland S 3rd, Bethoux FA, Boulis NM, Sutliff MH, Stough DK, Schwetz KM, et al.. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve. 2008;37(3):396&#x2013;8. Epub 2007/09/27. doi: 10.1002/mus.20900. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20900</ArticleId><ArticleId IdType="pubmed">17894358</ArticleId></ArticleIdList></Reference><Reference><Citation>Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology. 2010;112(1):165&#x2013;73. doi: 10.1097/ALN.0b013e3181c38da5. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3181c38da5</ArticleId><ArticleId IdType="pubmed">19996952</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al.. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12(11):1059&#x2013;67. Epub 2013/09/27. doi: 10.1016/S1474-4422(13)70221-7. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bujedo BM. Spinal opioid bioavailability in postoperative pain. Pain Pract. 2014;14(4):350&#x2013;64. Epub 2013/07/10. doi: 10.1111/papr.12099. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/papr.12099</ArticleId><ArticleId IdType="pubmed">23834413</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld GJ, van Kan HJ, Lie AHL, Guchelaar HJ, van den Berg LH. An association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin Pharmacol Ther. 2008;83(5):718&#x2013;22. doi: 10.1038/sj.clpt.6100382. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.clpt.6100382</ArticleId><ArticleId IdType="pubmed">17898704</ArticleId></ArticleIdList></Reference><Reference><Citation>Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg. 2011;112(2):460&#x2013;4. doi: 10.1213/ANE.0b013e318203b7c0. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e318203b7c0</ArticleId><ArticleId IdType="pubmed">21212256</ArticleId></ArticleIdList></Reference><Reference><Citation>NDA 20&#x2013;599 (1995). Riluzole Summary Basis of Approval (SBA) and associated documents. Received from FDA Freedom of Information Office by FOI Services Inc. (1999).</Citation></Reference><Reference><Citation>Butt MT. Morphologic changes associated with intrathecal catheters for direct delivery to the central nervous system in preclinical studies. Toxicol Pathol. 2011;39(1):213&#x2013;9. Epub 2010/12/15. doi: 10.1177/0192623310391679. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0192623310391679</ArticleId><ArticleId IdType="pubmed">21147930</ArticleId></ArticleIdList></Reference><Reference><Citation>Horais K, Hruby V, Rossi S, Cizkova D, Meschter C, Dorr R, et al.. Effects of chronic intrathecal infusion of a partial differential opioid agonist in dogs. Toxicol Sci. 2003;71(2):263&#x2013;75. Epub 2003/02/04. doi: 10.1093/toxsci/71.2.263. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/71.2.263</ArticleId><ArticleId IdType="pubmed">12563112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima RM, Navarro LH, Carness JM, Barros GA, Marques ME, Solanki D, et al.. Clinical and histological effects of the intrathecal administration of methylprednisolone in dogs. Pain Physician. 2010;13(5):493&#x2013;501. Epub 2010/09/23. .</Citation><ArticleIdList><ArticleId IdType="pubmed">20859319</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaksh TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, et al.. Chronically infused intrathecal morphine in dogs. Anesthesiology. 2003;99(1):174&#x2013;87. Epub 2003/06/27. doi: 10.1097/00000542-200307000-00028 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200307000-00028</ArticleId><ArticleId IdType="pubmed">12826858</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecht S, Huerta MM, Reed RB. Magnetic resonance imaging (MRI) spinal cord and canal measurements in normal dogs. Anat Histol Embryol. 2014;43(1):36&#x2013;41. Epub 2013/03/16. doi: 10.1111/ahe.12045. ; PubMed Central PMCID: PMC3933761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ahe.12045</ArticleId><ArticleId IdType="pmc">PMC3933761</ArticleId><ArticleId IdType="pubmed">23488993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105(1):169&#x2013;78. doi: 10.1097/00000542-200607000-00027 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200607000-00027</ArticleId><ArticleId IdType="pubmed">16810009</ArticleId></ArticleIdList></Reference><Reference><Citation>Busscher I, Ploegmakers JJ, Verkerke GJ, Veldhuizen AG. Comparative anatomical dimensions of the complete human and porcine spine. Eur Spine J. 2010;19(7):1104&#x2013;14. Epub 2010/02/27. doi: 10.1007/s00586-010-1326-9. ; PubMed Central PMCID: PMC2900026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-010-1326-9</ArticleId><ArticleId IdType="pmc">PMC2900026</ArticleId><ArticleId IdType="pubmed">20186441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratzsch T, Stienen MN, Reck T, Hildebrandt G, Hoederath P. Catheter-tip Granulomas Associated with Intrathecal Drug Delivery&#x2014;A Two-Center Experience Identifying 13 Cases. Pain Physician. 2015;18(5):E831&#x2013;40. Epub 2015/10/03. .</Citation><ArticleIdList><ArticleId IdType="pubmed">26431137</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer T, Krames ES, Hassenbusch S, Burton A, Caraway D, Dupen S, et al.. Management of intrathecal catheter-tip inflammatory masses: an updated 2007 consensus statement from an expert panel. Neuromodulation. 2008;11(2):77&#x2013;91. Epub 2008/04/01. doi: 10.1111/j.1525-1403.2008.00147.x. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1403.2008.00147.x</ArticleId><ArticleId IdType="pubmed">22151039</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer TR, Prager J, Levy R, Rathmell J, Buchser E, Burton A, et al.. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15(5):436&#x2013;64; discussion 64&#x2013;6. Epub 2012/07/04. doi: 10.1111/j.1525-1403.2012.00476.x. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1403.2012.00476.x</ArticleId><ArticleId IdType="pubmed">22748024</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, Jacob DA, Campos C, Miller DS, Maragakis NJ, Pasinelli P, et al.. Selective increase of two ABC drug efflux transporters at the blood-spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis. 2012;47(2):194&#x2013;200. doi: 10.1016/j.nbd.2012.03.040. ; PubMed Central PMCID: PMC3367047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.03.040</ArticleId><ArticleId IdType="pmc">PMC3367047</ArticleId><ArticleId IdType="pubmed">22521463</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al.. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14(3):262&#x2013;8. doi: 10.1111/j.1468-1331.2006.01575.x. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2006.01575.x</ArticleId><ArticleId IdType="pubmed">17355545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al.. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416&#x2013;22. Epub 2018/03/12. doi: 10.1016/S1474-4422(18)30054-1. ; PubMed Central PMCID: PMC5899963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>